Aripiprazole Tablet
Product Images NDC 70518-2281

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2281). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole 10mg 70518 2281 02

Aripiprazole Tablet 10 mg oral tablets packaging label showing quantity of 30 tablets. The label includes NDC 70518-2281-02, repackaged by RemedyRepack Inc., Indiana, PA. The original manufacturer is Alembic Pharma, Bridgewater, NJ. Storage instructions and lot number fields are also visible.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

This chart depicts fold changes and 90% confidence intervals for pharmacokinetic parameters (AUC and Cmax) of various drugs when coadministered, relative to a reference without interacting drug. The vertical axis lists drugs such as dextromethorphan, warfarin (R and S forms), omeprazole, lamotrigine, valproate, lithium, lorazepam, and venlafaxine. The horizontal axis shows change relative to reference values, from 0.5 to 3 fold.*

FDA Label Image

Aripiprazole Fig 6

A line graph comparing the proportion of subjects with relapse over time for Aripiprazole versus placebo. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. Two lines represent Aripiprazole (solid) and placebo (dashed), with subjects at risk listed below the x-axis at various time points.*

FDA Label Image

Aripiprazole Fig 9

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment for Aripiprazole low dose, Aripiprazole high dose, and placebo groups. The y-axis represents the least-squares mean change in YGTSS total tic score, and the x-axis represents weeks of treatment from 0 to 8. Both Aripiprazole groups show a greater reduction in tic score compared to placebo over time.*

FDA Label Image

Figure 7 (Aripiprazole Figur7)

A Kaplan-Meier curve comparing the proportion of subjects experiencing relapse over days from randomization between Aripiprazole and placebo groups. The graph shows the relapse proportion increasing over time, with Aripiprazole group (solid line) exhibiting a lower relapse proportion than placebo (dashed line). Below the x-axis is a table indicating the number of subjects at risk at multiple time points up to 182 days.*

FDA Label Image

Aripiprazole Figure1

A scatter plot showing the effects of various other drugs on Aripiprazole pharmacokinetics, specifically AUC and Cmax fold changes with 90% confidence intervals. The chart compares inhibitors, inducers, gastric acid blockers, and other drugs based on their impact on Aripiprazole exposure relative to a reference without interacting drugs.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A forest plot chart showing the effect of various drugs on the pharmacokinetic parameters (AUC and Cmax) of Aripiprazole. It compares the fold change and 90% confidence intervals relative to a reference without interacting drugs for CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam).*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

A pharmacokinetic chart showing aripiprazole fold change and 90% confidence intervals for special populations. Variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, with pharmacokinetic parameters AUC and Cmax plotted as fold changes relative to a reference group.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A pharmacokinetic chart showing fold change and 90% confidence intervals for dehydro-aripiprazole levels. The chart compares variables such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment against reference levels, using AUC and Cmax measurements along the Y-axis and fold change relative to reference on the X-axis.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, showing its molecular framework with labeled chlorine atoms and ring systems characteristic of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.